Qatar’s Ministry of Public Health has ordered the recall of all batches of Ferinject 50 mg/mL, an intravenous iron medication, after laboratory tests found that the product did not meet the manufacturer’s stated chemical specifications.
In a statement, the ministry said its laboratories had identified the non-compliance during testing and instructed that all shipments of the medicine be withdrawn from the market.
Ferinject, also known by its generic name ferric carboxymaltose, is used to treat iron-deficiency anaemia in patients who cannot take oral iron supplements, do not respond adequately to them or require intravenous treatment for clinical reasons.
The ministry urged members of the public who had purchased the medicine to stop using it immediately. It also reaffirmed its commitment to protecting patients and ensuring that pharmaceutical products available in Qatar meet required quality and safety standards.
The latest action follows a series of pharmaceutical recalls in Qatar, including two involving eye drops.
On the previous day, authorities announced the withdrawal of all batches of Isotears-Plus lubricating eye drops over manufacturing defects. The product is used to provide temporary relief from burning, irritation and discomfort associated with dry eyes and environmental exposure.
Earlier, Qatar also recalled all batches of Clasgen 0.05 per cent eye drops after concerns were identified involving data integrity and sterile manufacturing processes.
Product recalls across the Gulf
Similar precautionary measures have been taken in the United Arab Emirates over recent months, involving medicines and other healthcare products.
Last month, UAE authorities ordered the recall of batch number 20251015 of Nin 160 FMB-NML blue three-ply face masks following a quality complaint. Subsequent inspections identified foreign material or possible contamination in units from the affected batch.
Dubai also recalled certain batches of Babies’ Magic Tea, marketed as Baby Sleep Gripe Water, after undeclared alcohol content was identified and concerns were raised over the product’s lack of valid marketing authorisation.
The recall covered batch number 25122bw and followed a circular issued by the Emirates Drug Establishment. The notice was distributed to clinics and healthcare professionals, with the Dubai Health Authority also informing relevant providers. Authorities said the action was intended to protect the health and safety of infants.
UAE residents have also been encouraged to report suspected side effects after taking medicines as part of a nationwide effort to strengthen medicine safety monitoring.
The latest recalls highlight the role of regulatory testing and product monitoring in identifying quality concerns and removing affected healthcare products from circulation. Authorities have urged consumers to follow official recall notices and seek advice from healthcare professionals when necessary.
